Clinical trial · Interventional
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
NCT06330012CI-TRIAL-00075404recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2-positive Breast Cancer | HER2-Positive Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GeoMx data analysis with clinical outcome | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Spatial transcriptomic approch
- description
- Spatial transcriptomic approch for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
- interventionNames
- Diagnostic Test: GeoMx data analysis with clinical outcome
Primary outcomes (1)
- measure
- Spatial transcriptomic analysis
- timeFrame
- Before chemotherapy, curative surgery
- description
- Protein expression and relationship protein-protein in HER2 positive breast cancer tumor cells and tumor microenvironment.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples Exclusion Criteria: * TNBC breast cancer * Hormone receptor positive breast cancer * Non-available FFPE samples * Treated except T-Dxd
References
Publications (0)
Data not yet available
No reference posted for this study.